[go: up one dir, main page]

NO20092067L - 5-(heterosyklyl)alkyl-n- (arylsulfonyl)indolforbindelserog deres anvendelse som 5-HT6-ligander - Google Patents

5-(heterosyklyl)alkyl-n- (arylsulfonyl)indolforbindelserog deres anvendelse som 5-HT6-ligander

Info

Publication number
NO20092067L
NO20092067L NO20092067A NO20092067A NO20092067L NO 20092067 L NO20092067 L NO 20092067L NO 20092067 A NO20092067 A NO 20092067A NO 20092067 A NO20092067 A NO 20092067A NO 20092067 L NO20092067 L NO 20092067L
Authority
NO
Norway
Prior art keywords
disorders
compounds
pharmaceutically acceptable
arylsulfonyl
heterocyclyl
Prior art date
Application number
NO20092067A
Other languages
English (en)
Other versions
NO341713B1 (no
Inventor
Rama Sastri Kambhampati
Venkateswarlu Jasti
Nirogi Venkata Satya Ramakrishna
Jagadishbabu Konda
Prabhakar Kothmirkar
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of NO20092067L publication Critical patent/NO20092067L/no
Publication of NO341713B1 publication Critical patent/NO341713B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Det beskrives nye 5-(heterosyklyl)alkyl-N-(arylsulfonyl)in-dolforbindelser med formel (I), samt deres derivater, stereoisomerer, farmasøytisk akseptable salter og farmasøytisk akseptable preparater som inneholder forbindelsene. Det beskrives videre en fremgangsmåte for fremstilling av nevnte nye forbindelser, deres derivater, stereoisomerer, deres farmasøytisk akseptable salter og farmasøytisk akseptable preparater inneholdende disse. Forbindelsene er nyttige ved behandling av forskjellige forstyrrelser som er relatert til 5-HT6-reseptorfunksjoner. Spesielt er forbindelsene ifølge oppfinnelsen også nyttige ved behandling av forskjellige CNS-forstyrrelser, hematologiske forstyrrelser, spiseforstyrrelser, sykdommer assosiert med smerte, respiratoriske sykdommer, genitourologiske forstyrrelser, kardiovaskulære sykdommer og cancer.
NO20092067A 2007-01-08 2009-05-27 5-(Heterosyklyl)alkyl-n-(arylsulfonyl)indolforbindelser og deres anvendelse som 5-HT6-ligander NO341713B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN45CH2007 2007-01-08
PCT/IN2007/000312 WO2008084492A1 (en) 2007-01-08 2007-07-26 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands

Publications (2)

Publication Number Publication Date
NO20092067L true NO20092067L (no) 2009-09-04
NO341713B1 NO341713B1 (no) 2018-01-08

Family

ID=39495814

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092067A NO341713B1 (no) 2007-01-08 2009-05-27 5-(Heterosyklyl)alkyl-n-(arylsulfonyl)indolforbindelser og deres anvendelse som 5-HT6-ligander

Country Status (22)

Country Link
US (1) US8470830B2 (no)
EP (1) EP2114878B1 (no)
JP (1) JP2010515674A (no)
KR (1) KR101103023B1 (no)
CN (1) CN101553467B (no)
AT (1) ATE491685T1 (no)
AU (1) AU2007343063B2 (no)
BR (1) BRPI0718737A2 (no)
CA (1) CA2670717C (no)
CY (1) CY1111105T1 (no)
DE (1) DE602007011323D1 (no)
DK (1) DK2114878T3 (no)
EA (1) EA017007B1 (no)
ES (1) ES2357584T3 (no)
IL (1) IL198821A (no)
MX (1) MX2009006077A (no)
NO (1) NO341713B1 (no)
NZ (1) NZ577769A (no)
PL (1) PL2114878T3 (no)
PT (1) PT2114878E (no)
WO (1) WO2008084492A1 (no)
ZA (1) ZA200903600B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010032257A1 (en) * 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
CN103304547A (zh) * 2012-03-13 2013-09-18 中国药科大学 一种抗抑郁药维拉唑酮的制备方法
JP2016538309A (ja) * 2013-11-25 2016-12-08 ノボゲン リミテッドＮｏｖｏｇｅｎ Ｌｔｄ 抗がん剤としての官能化及び置換インドール
EP3083588B1 (en) 2013-12-20 2020-12-09 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
US9974785B2 (en) 2014-07-08 2018-05-22 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
JP2017520612A (ja) * 2014-07-16 2017-07-27 ノボジェン リミティッド 抗がん剤としての官能化され置換されたインドール
CA3182412A1 (en) * 2020-07-06 2022-01-13 Mathew BAGGOTT Advantageous benzothiophene compositions for mental disorders or enhancement

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9026389D0 (en) * 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
PL338016A1 (en) 1997-07-11 2000-09-25 Smithkline Beecham Plc Novel chemical compounds
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
CA2370147C (en) 1999-04-21 2009-07-28 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-ht6 affinity
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
CN1222511C (zh) * 2000-11-02 2005-10-12 惠氏公司 作为5－羟色胺－6配体的1－芳基－或1－烷基磺酰基－杂环基吲哚
ATE340795T1 (de) 2001-01-30 2006-10-15 Lilly Co Eli Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
CN100439370C (zh) 2001-02-08 2008-12-03 记忆药物公司 作为磷酸二酯酶4抑制剂的三氟甲基嘌呤
KR100600240B1 (ko) 2001-06-07 2006-07-13 에프. 호프만-라 로슈 아게 5-ｈｔ6 수용체 친화도를 갖는 신규한 인돌 유도체
EP1414442A1 (en) 2001-08-07 2004-05-06 Smithkline Beecham Plc 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
JP2005528587A (ja) 2002-02-01 2005-09-22 バイエル・ヘルスケア・アクチェンゲゼルシャフト 新規ヒト５−ｈｔ６受容体に関連する疾患のための診断用および治療用物質
EP1471912A1 (en) 2002-02-05 2004-11-03 Glaxo Group Limited Method of promoting neuronal growth
US7452888B2 (en) 2002-03-27 2008-11-18 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
CN101544592B (zh) 2002-11-28 2013-08-21 苏文生命科学有限公司 N-芳基磺酰-3-取代吲哚制备的替代方法
WO2004048331A1 (en) 2002-11-28 2004-06-10 Suven Life Sciences Limited N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands
CA2507505C (en) 2002-11-28 2011-10-04 Suven Life Sciences Limited N-arylsulfonyl-3-aminoalkoxyindoles
WO2004055026A1 (en) 2002-12-18 2004-07-01 Suven Life Sciences Limited Tetracyclic 3-substituted indoles having serotonin receptor affinity
WO2004108671A1 (en) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
ES2222828B1 (es) 2003-07-30 2006-04-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos.
NZ566495A (en) 2005-08-12 2010-06-25 Suven Life Sciences Ltd Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands
EP2046741B1 (en) * 2006-07-03 2012-10-31 Proximagen Ltd. Indoles as 5-ht6 modulators

Also Published As

Publication number Publication date
IL198821A (en) 2014-11-30
PL2114878T3 (pl) 2011-05-31
ATE491685T1 (de) 2011-01-15
US20100041673A1 (en) 2010-02-18
CY1111105T1 (el) 2015-06-11
JP2010515674A (ja) 2010-05-13
EA017007B1 (ru) 2012-09-28
CN101553467A (zh) 2009-10-07
AU2007343063A1 (en) 2008-07-17
AU2007343063B2 (en) 2011-02-17
BRPI0718737A2 (pt) 2014-03-25
EP2114878B1 (en) 2010-12-15
CA2670717C (en) 2012-01-10
ZA200903600B (en) 2010-07-28
EP2114878A1 (en) 2009-11-11
KR20090080544A (ko) 2009-07-24
DK2114878T3 (da) 2011-03-14
ES2357584T3 (es) 2011-04-27
AU2007343063A8 (en) 2009-07-23
MX2009006077A (es) 2009-06-17
EA200970675A1 (ru) 2009-12-30
KR101103023B1 (ko) 2012-01-05
DE602007011323D1 (de) 2011-01-27
HK1132273A1 (en) 2010-02-19
NO341713B1 (no) 2018-01-08
IL198821A0 (en) 2010-02-17
NZ577769A (en) 2011-01-28
CN101553467B (zh) 2011-12-07
US8470830B2 (en) 2013-06-25
PT2114878E (pt) 2011-03-10
CA2670717A1 (en) 2008-07-17
WO2008084492A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
MY192354A (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
MY167135A (en) Fused heterocyclic derivatives and methods of use
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
MY156822A (en) Indole derivatives as s1p1 receptor agonists
NO20092067L (no) 5-(heterosyklyl)alkyl-n- (arylsulfonyl)indolforbindelserog deres anvendelse som 5-HT6-ligander
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX2007002393A (es) Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6).
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
CY1111836T1 (el) Ενωσεις aminoalkoxy aryl sulfonamide και η χρηση τους σαν συνδετων (ligands) 5-ητ6
EA200970849A1 (ru) Трициклические производные изохинолина для лечения ожирения
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
MX2009006757A (es) Compuestos de 4-(heterociclil)alquil-n-(arilsulfonil) indol y su uso como ligandos de la 5-hidroxitriptamina6.
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
CY1112181T1 (el) Αμινο αρυλοσουλφοναμιδικες ενωσεις και η χρηση τους ως 5-ητ6 συνδετες
MX2011008857A (es) Derivados de oxiindol con actividad agonistica del receptor de motilina.
WO2014147636A8 (en) 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы
PL1732902T3 (pl) Pochodne nukleozydów i ich terapeutyczne zastosowanie
WO2010012806A3 (en) Substituted indole sulfonamide compounds, their preparation and use as medicaments

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees